No Data
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for Pegunigalsidase Alfa
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript Summary
Protalix BioTherapeutics Reports Profit In Q3; Announces Positive Phase 1 Data For PRX-115
Protalix BioTherapeutics Q3 24 Earnings Conference Call At 8:30 AM ET
Protalix Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Protalix Biotherapeutics | 8-K: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results